Expanding mRNA Technology Beyond Vaccines

 

mRNA Technology Beyond Vaccines

Messenger RNA (mRNA) technology has evolved from a niche research concept to a transformative force in global healthcare. While the COVID-19 pandemic accelerated its visibility, the scope of mRNA extends far beyond vaccines. From oncology to rare genetic diseases, mRNA-based therapeutics are reshaping the way diseases are treated, driving both clinical innovation and regulatory recalibration.

For pharmaceutical companies, this rapid evolution creates a dual challenge: navigating complex approval frameworks while staying ahead in a highly competitive innovation race. Understanding the current regulatory landscape and how it is adapting to novel modalities like mRNA is critical for ensuring market readiness and long-term success.

Current Status of mRNA Technology

The success of COVID-19 vaccines from Moderna and Pfizer-BioNTech demonstrated the scalability and speed of mRNA deployment. A major milestone followed in May 2024, when the U.S. FDA approved Moderna’s RSV vaccine (mRESVIA) for adults aged 60+. In September 2025, the FDA further expanded its indication to include adults 18–59 at higher risk of RSV infection. These approvals highlight growing regulatory confidence in the adaptability and safety of mRNA beyond COVID-19.

mRNA technology leverages the body’s own cellular machinery to produce therapeutic proteins in vivo, rather than delivering proteins directly. This enables a versatile platform across infectious diseases, oncology, rare genetic conditions, and regenerative medicine.

The global mRNA therapeutics market is projected to reach USD 42.6 billion by 2034 at a CAGR of ~8.3% (BioSpace, 2025), underscoring its expanding role in modern medicine.

How Translational Biology Is Fast-Tracking Tomorrow’s Therapies

Read the blog in detail about mRNA technology from DDReg Experts: How mRNA Technology Is Expanding Beyond Vaccines — DDReg pharma

Comments

Post a Comment

Popular posts from this blog

Risk Management in Regulatory Affairs: Mitigating Compliance Risks

Image
Pharmaceutical companies face significant challenges in navigating a stringent and constantly evolving regulatory environment, coupled with technological advancements and global economic considerations. Assessing and managing risks is vital throughout the entire life cycle of a pharmaceutical product, from research and clinical testing to manufacturing and distribution. Organizations must demonstrate to regulatory authorities that they have a well-documented plan to identify, measure, control, and monitor the various risks. The pharmaceutical industry is highly regulated for good reason, given the critical importance of safety, efficacy, and the impact that medicines and treatments can have on patient’s lives. Regulatory scrutiny spans various aspects of pharmaceutical operations, including sales and marketing, drug price reporting, patient privacy, clinical trials and procedures, preclinical work and testing, and manufacturing. Consequently, ensuring compliance with regulatory affairs...
Read more

The Benefits of Partnering with Regulatory Consultants

Image
Pharmaceutical organizations that are not compliant with regulations set by the authorities can face severe consequences that can significantly impact the organization in terms of cost and reputational damage. Regulatory service providers must also ensure that their services and quality systems are compliant with regulations and current good manufacturing practices (cGMP). Companies that are not cGMP compliant or follow strict quality parameters could be problematic and lead to product recall. Therefore, it is important to partner with a pharma regulatory affairs consulting team or service that can, for example, assist in responding to queries or regulatory conc erns or navigate through quality system audits to ensure regulatory compliance is met. When identifying the right regulatory consulting firms it is important to make sure that they possess recent and extensive experience in the regulatory domain. They must also be able to demonstrate their knowledge of the regulatory land...
Read more

Customer Due Diligence: Meeting Regulatory Expectations

Image
In today's business landscape, regulatory compliance is a cornerstone of trust and integrity. Nowhere is this more evident than in the realm of customer due diligence (CDD). Financial institutions, businesses dealing with high-value transactions, and even online platforms must adhere to stringent CDD requirements to mitigate risks associated with money laundering, terrorism financing, and other illicit activities. Meeting regulatory expectations in CDD is not just about ticking boxes; it's about safeguarding against financial crime while fostering trust with customers. Let's delve into how businesses can navigate this complex landscape effectively. Understanding Customer Due Diligence Customer due diligence refers to the process of verifying the identity of customers, assessing the risks they pose, and understanding the nature of their transactions. It involves collecting relevant information about customers, such as their identity, address, and source of funds, to ensure c...
Read more